Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Neos Therapeutics, Inc. (NEOS)
|
Add to portfolio |
|
|
|
| Price: |
$0.92
| | Metrics |
| OS: |
49.8
|
M
| |
|
|
| Market cap: |
$45.8
|
M
| |
-1304
|
% ROIC
|
|
Net debt:
|
$27.8
|
M
| |
|
|
|
EV:
|
$73.5
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($13.0)
|
M
| |
|
|
|
EBIT
|
($13.5)
|
M
| |
|
|
| EPS |
($0.44)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 |
| Revenues | 64.6 | 50.0 | 27.1 | 10.0 | 3.8 | 0.8 | 1.0 |
| Revenue growth | 29.3% | 84.2% | 170.4% | 164.6% | 400.3% | -27.4% | |
| Cost of goods sold | 25.1 | 26.9 | 14.0 | 11.7 | 5.9 | 3.4 | 2.5 |
| Gross profit | 39.5 | 23.1 | 13.1 | -1.7 | -2.1 | -2.6 | -1.5 |
| Gross margin | 61.1% | 46.1% | 48.3% | -17.0% | -56.4% | -347.4% | -142.7% |
| Sales and marketing | 28.1 | 44.1 | 46.9 | 49.3 | 5.7 | 0.2 | 0.2 |
| Research and development | 8.6 | 8.5 | 9.0 | 12.2 | 11.7 | 10.6 | 10.0 |
| General and administrative | 13.2 | 13.9 | 13.8 | 12.6 | 7.1 | 5.0 | 5.5 |
| EBITA | -9.6 | -41.5 | -54.9 | -74.2 | -25.1 | -17.4 | -16.2 |
| EBITA margin | -14.9% | -83.1% | -202.3% | -739.2% | -660.9% | -2296.0% | -1556.1% |
| Amortization of intangibles | 1.7 | 1.7 | 1.7 | 1.7 | 1.5 | 1.1 | 0.8 |
| EBIT | -11.4 | -43.3 | -56.5 | -75.8 | -26.6 | -18.5 | -17.1 |
| EBIT margin | -17.6% | -86.6% | -208.4% | -755.7% | -700.9% | -2436.9% | -1636.8% |
| Pre-tax income | -16.9 | -51.7 | -65.8 | -82.8 | -30.8 | -20.8 | -18.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net income | -16.9 | -51.7 | -65.8 | -82.8 | -33.2 | -24.2 | -22.4 |
| Net margin | -26.1% | -103.4% | -242.4% | -824.8% | -874.8% | -3186.3% | -2150.3% |
| |
| Diluted EPS | ($0.34) | ($1.60) | ($2.66) | ($5.16) | ($4.38) | ($27.56) | ($28.45) |
| Shares outstanding (diluted) | 49.7 | 32.3 | 24.8 | 16.1 | 7.6 | 0.9 | 0.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|